Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2022-06-02 Regulatory Filings
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-06-02 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references the Securities Act of 1933 and is a formal communication related to a securities registration process. The document is short (1618 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an official regulatory filing related to the registration process. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance communication to the SEC rather than a financial report or announcement of a report.
2022-05-31 English
Director's Dealing 2022
Director's Dealing
2022-05-27 English
Director's Dealing 2022
Director's Dealing
2022-05-23 English
S-3/A
Regulatory Filings Classification · 100% confidence The document is titled 'Amendment No. 1 to Form S-3 Registration Statement' filed with the SEC. It references the Securities Act of 1933 and is a registration statement for Gain Therapeutics, Inc. The content includes exhibits, consents from auditors, underwriting agreements, and signatures of officers and directors. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing related to securities registration and amendments to that registration, not a financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS).
2022-05-23 English
Director's Dealing 2022
Director's Dealing
2022-05-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.